Hanadie Yousef, PhD

Chief Executive Officer and Co-Founder, Juvena Therapeutics
Dr. Hanadie Yousef is an entrepreneur, scientist, and leading expert on the mechanisms underlying age-related tissue degeneration with over two decades of experience in biomedical research. In 2018, she launched Juvena Therapeutics, a venture-backed, platform-driven, clinical stage biotechnology company mapping the therapeutic potential of secreted proteins and accelerating their translation into engineered biologics that promote tissue repair and restoration of function and health to treat degenerative diseases.
Under Dr. Yousef’s leadership, Juvena has leveraged its Artificial Intelligence (AI)-enabled platform to develop a proprietary, pro-regenerative protein library that enabled the discovery and development of a growing pipeline of biologics for muscle and metabolic diseases. The company’s lead asset, JUV-161, promotes muscle regeneration and metabolism. As of Q2 2025, it is in Phase 1 safety studies for the treatment of orphan disease Myotonic Dystrophy Type and sarcopenia. In addition, Juvena is progressing multiple preclinical programs across metabolic and fibrotic disease areas, including a novel preclinical obesity asset, JUV-112, that uniquely enhances lipid metabolism to induce weight loss through an energy expenditure promoting, non appetite-suppressing mechanism.
Dr. Yousef’s high-impact published research has been supported by fellowships and grants from the National Institute of Health (NIH), National Science Foundation, SPARK, and the California Institute for Regenerative Medicine and led to multiple issued and pending patents. She has received multiple awards and recognition for her entrepreneurship and innovation, including San Francisco Business Times’ “Women Who Lead in Life Sciences”, In Vivo’s “Rising Leaders“, and Founders Forum’s “100 Women Founders to Watch” in 2024, FierceBiotech’s “Fiercest Women in Life Sciences,” Business Insider’s “30 Leaders Under 40 Changing Healthcare in 2023,” Endpoints’ “The 20(+2) under 40,” and Pharmaceutical Executive’s “Emerging Pharma Leader”in 2023, , and the 2022 Biocom Catalyst award. She is also a regularly invited speaker at industry and innovation events. Under her leadership, Juvena has been recognized as the “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year” by BioSpace and as a World Economic Forum 2024 Technology Pioneer company.
Dr. Yousef earned her B.S., summa cum laude from Carnegie Mellon University and a PhD from UC Berkeley as an NSF graduate research fellow then completed a 5-year postdoctoral fellowship at Stanford School of Medicine as an NIH fellow and SPARK scholar.
Learn more about Hanadie
LinkedIn
PubMed Library
PostDoc Research